Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162984346> ?p ?o ?g. }
- W2162984346 endingPage "3271" @default.
- W2162984346 startingPage "3264" @default.
- W2162984346 abstract "ABSTRACT The aim of the present study was to obtain clinical experience with the use of high-dose ciprofloxacin as monotherapy for the treatment of febrile neutropenia episodes (granulocyte count, <500/mm 3 ) compared to a standard regimen and to clarify whether ciprofloxacin administration may be switched to the oral route. In a prospective randomized study ciprofloxacin was given at 400 mg three times a day (t.i.d.) for at least 72 h followed by oral administration at 750 mg twice a day (b.i.d). That regimen was compared with ceftazidime given intravenously at 2 g t.i.d. plus amikacin given intravenously at 500 mg b.i.d. The frequency of successful clinical response without modification at the end of therapy was almost identical for ciprofloxacin (50% [62 of 124 patients]) compared with that for ceftazidime plus amikacin (50.8% [62 of 122 patients]) in an intent-to-treat analysis; the frequencies were 48.3% (57 of 118 patients) versus 49.6% (56 of 113 patients), respectively, in a per-protocol analysis ( P values for one-sided equivalence, 0.0485 and 0.0516, respectively; δ = 10%), with no significant differences among patients with bacteremia and other microbiologically or clinically documented infections and fever of unknown origin. For 82 (66.1%) patients, it was possible to switch from parenteral ciprofloxacin to the oral ciprofloxacin, and the response was successful for 61 (74.4%) patients. The efficacies of the regimens against streptococcal bacteremias were 16.6% (one of six patients) for the ciprofloxacin group and 33.3% (one of three patients) for the combination group (it was not statistically significant), with one breakthrough streptococcal bacteremia observed among the ciprofloxacin-treated patients. Adverse events were mostly self-limited and were observed in 27 (20.6%) ciprofloxacin-treated patients and 26 (19.7%) patients who were receiving the combination. This study demonstrates that high-dose ciprofloxacin given intravenously for at least 3 days and then by the oral route is therapeutically equivalent to the routine regimen of intraveneous ceftazidime plus amikacin even in febrile patients with severe neutropenia (polymorphonuclear leukocyte count, <100 mm 3 ). However, it is very important that before an empirical therapy is chosen each hospital determine bacteriologic predominance and perform resistance surveillance." @default.
- W2162984346 created "2016-06-24" @default.
- W2162984346 creator A5017988940 @default.
- W2162984346 creator A5020621501 @default.
- W2162984346 creator A5045515497 @default.
- W2162984346 creator A5048001001 @default.
- W2162984346 creator A5049027344 @default.
- W2162984346 creator A5052146006 @default.
- W2162984346 creator A5064861218 @default.
- W2162984346 creator A5087043342 @default.
- W2162984346 date "2000-12-01" @default.
- W2162984346 modified "2023-10-02" @default.
- W2162984346 title "Monotherapy with Intravenous Followed by Oral High-Dose Ciprofloxacin versus Combination Therapy with Ceftazidime plus Amikacin as Initial Empiric Therapy for Granulocytopenic Patients with Fever" @default.
- W2162984346 cites W1571178250 @default.
- W2162984346 cites W1962928558 @default.
- W2162984346 cites W1981035539 @default.
- W2162984346 cites W1991642887 @default.
- W2162984346 cites W2020378106 @default.
- W2162984346 cites W2041732953 @default.
- W2162984346 cites W2043977100 @default.
- W2162984346 cites W2054759723 @default.
- W2162984346 cites W2057760541 @default.
- W2162984346 cites W2058806060 @default.
- W2162984346 cites W2066818422 @default.
- W2162984346 cites W2084249228 @default.
- W2162984346 cites W2096104385 @default.
- W2162984346 cites W2096691209 @default.
- W2162984346 cites W2102237290 @default.
- W2162984346 cites W2108818954 @default.
- W2162984346 cites W2112104251 @default.
- W2162984346 cites W2117348787 @default.
- W2162984346 cites W2118765654 @default.
- W2162984346 cites W2157620025 @default.
- W2162984346 cites W2169482637 @default.
- W2162984346 cites W2319983332 @default.
- W2162984346 cites W2335721167 @default.
- W2162984346 cites W2341879580 @default.
- W2162984346 cites W2995475181 @default.
- W2162984346 cites W3022798003 @default.
- W2162984346 cites W4233132580 @default.
- W2162984346 cites W4239478520 @default.
- W2162984346 doi "https://doi.org/10.1128/aac.44.12.3264-3271.2000" @default.
- W2162984346 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/90190" @default.
- W2162984346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11083625" @default.
- W2162984346 hasPublicationYear "2000" @default.
- W2162984346 type Work @default.
- W2162984346 sameAs 2162984346 @default.
- W2162984346 citedByCount "58" @default.
- W2162984346 countsByYear W21629843462012 @default.
- W2162984346 countsByYear W21629843462013 @default.
- W2162984346 countsByYear W21629843462014 @default.
- W2162984346 countsByYear W21629843462015 @default.
- W2162984346 countsByYear W21629843462016 @default.
- W2162984346 countsByYear W21629843462017 @default.
- W2162984346 countsByYear W21629843462018 @default.
- W2162984346 countsByYear W21629843462023 @default.
- W2162984346 crossrefType "journal-article" @default.
- W2162984346 hasAuthorship W2162984346A5017988940 @default.
- W2162984346 hasAuthorship W2162984346A5020621501 @default.
- W2162984346 hasAuthorship W2162984346A5045515497 @default.
- W2162984346 hasAuthorship W2162984346A5048001001 @default.
- W2162984346 hasAuthorship W2162984346A5049027344 @default.
- W2162984346 hasAuthorship W2162984346A5052146006 @default.
- W2162984346 hasAuthorship W2162984346A5064861218 @default.
- W2162984346 hasAuthorship W2162984346A5087043342 @default.
- W2162984346 hasBestOaLocation W21629843461 @default.
- W2162984346 hasConcept C126322002 @default.
- W2162984346 hasConcept C141071460 @default.
- W2162984346 hasConcept C2776694085 @default.
- W2162984346 hasConcept C2776968632 @default.
- W2162984346 hasConcept C2776999253 @default.
- W2162984346 hasConcept C2777063308 @default.
- W2162984346 hasConcept C2777427914 @default.
- W2162984346 hasConcept C2777637488 @default.
- W2162984346 hasConcept C2778512257 @default.
- W2162984346 hasConcept C2778850193 @default.
- W2162984346 hasConcept C2779443120 @default.
- W2162984346 hasConcept C2780608335 @default.
- W2162984346 hasConcept C2781413609 @default.
- W2162984346 hasConcept C3019249092 @default.
- W2162984346 hasConcept C501593827 @default.
- W2162984346 hasConcept C523546767 @default.
- W2162984346 hasConcept C54355233 @default.
- W2162984346 hasConcept C71924100 @default.
- W2162984346 hasConcept C86803240 @default.
- W2162984346 hasConcept C89423630 @default.
- W2162984346 hasConcept C90924648 @default.
- W2162984346 hasConceptScore W2162984346C126322002 @default.
- W2162984346 hasConceptScore W2162984346C141071460 @default.
- W2162984346 hasConceptScore W2162984346C2776694085 @default.
- W2162984346 hasConceptScore W2162984346C2776968632 @default.
- W2162984346 hasConceptScore W2162984346C2776999253 @default.
- W2162984346 hasConceptScore W2162984346C2777063308 @default.
- W2162984346 hasConceptScore W2162984346C2777427914 @default.
- W2162984346 hasConceptScore W2162984346C2777637488 @default.
- W2162984346 hasConceptScore W2162984346C2778512257 @default.
- W2162984346 hasConceptScore W2162984346C2778850193 @default.
- W2162984346 hasConceptScore W2162984346C2779443120 @default.